Progress on breast cancer therapy with vitamin Q10 and the regression of metastases

Lockwood K; Moesgaard S; Yamamoto T; Folkers K
Pharma Nord, Vejle, Denmark
Biochem Biophys Res Commun (U.S.)Jul 6 1995, 212 (1) P172-7

Over 39 years, data and knowledge have internationally evoked from biochemical, biomedical and clinical research on vitamin Q10 (coenzyme Q10; CoQ10) and cancer which led in 1993 to overt complete regression of the tumors in two cases of breast cancer. Continuing this research, three additional breast cancer patients also underwent a conventional protocol of therapy which included a daily oral dosage of 390 mg of vitamin Q10 (Bio-Quinone of Pharma Nord) during the complete trials over 3-5 years.

The numerous metastases in the liver of a 44-year-old patient "disappeared and no signs of metastases were found elsewhere. A 49- year-old patient, on a dosage of 590 mg of vitamin Q10, revealed no signs of tumor in the plural cavity after six months, and her condition was excellent. A 75-year-old patient with carcinoma in one breast, after lumpectomy and 390 mg of CoQ10, showed no cancer in the tumor bed or metastases. Control blood levels of CoQ10 of 0.89-0.97 and of 0.62 micrograms/mi increased to 3.34- 3.64 and to 3.77 micrograms/ml, respectively on therapy with CoQ10 for patients A-MRH and EEL.

Survival of cancer patients on therapy with coenzyme Q10

Folkers K; Brown R; Judy WV; Morita Y
University of Texas, Austin.
Biochem Biophys Res Comnun (U.S.) Apr 15 1993, 192 (1) p241-5,

Over 25 years, assays in animal models established the hematopoietic activities of coenzyme Q's in rhesus monkeys, rabbits, poultry, and children having kwashiorkor. Surprisingly a virus was found to cause a deficiency of CoQ10. Patients with AIDS showed a-"striking"-clinical response to therapy with CoQ10. The macrophage potentiating activity of CoQ10 was recorded by the carbon clearance method. CoQ10 significantly increased the levels of IgG in patients. Eight new case histories of cancer patients plus two reported cases support the statement that therapy of cancer patients with CoQ10, which has no significant side effect, has allowed survival on an exploratory basis for periods of 5-15 years. These results now justify systematic protocols. (15 Refs.)

Partial and complete regression of breast cancer in patients in relation to Coenzyme Q10 dosage

Lockwood K; Moesgaard S; FoIkers K
Pharma Nord, Vejle, Denmark
Biochem Biophys Res Commun (U.S.) Mar 30 1994, 199 (3) pI504-8

Relationships of nutrition and vitamins to the genesis and prevention of cancer are increasingly evident. In a clinical protocol, 32 patients having "high-risk" breast cancer were treated with antioxidants, fatty acids, and 90 mg of CoQ10.

Six of the 32 patients showed partial tumor regression. In one of these 6 cases the dosage of CoQ10 was increased to 390 mg. In one month, the tumor was no longer palpable and in another month, mammography confirmed the absence of tumor. Encouraged, another case having a verified breast tumor after non-radical surgery and with verified residual tumor in the tumor bed was then treated with 300 mg CoQ10. After 3 months, the patient was in excellent clinical condition and there was no residual tumor tissue. The bio energetic activity of CoQ10, expressed as hematological or immunological activity, may be the dominant but not the sole molecular mechanism causing the regression of breast cancer.